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Abstract
A single intra-articular injection of adeno-associated virus (AAV) results in stable and controllable transgene
expression in normal rat knees. Because undamaged joints are unlikely to require treatment, the study of AAV
delivery in joint injury models is crucial to potential therapeutic applications. This study tests the hypotheses
that persistent and controllable AAV-transgene expression are (1) highly localized to the cartilage when AAV is
injected postinjury and (2) localized to the intra-articular soft tissues when AAV is injected preinjury. Two AAV
injection time points, postinjury and preinjury, were investigated in osteochondral defect and anterior cruciate
ligament transection models of joint injury. Rats injected with AAV tetracycline response element (TRE)–lucif-
erase received oral doxycycline for 7 days. Luciferase expression was evaluated longitudinally for 6 months.
Transgene expression was persistent and controllable with oral doxycycline for 6 months in all groups. How-
ever, the location of transgene expression was different: postinjury AAV-injected knees had luciferase expression
highly localized to the cartilage, while preinjury AAV-injected knees had more widespread signal from intra-
articular soft tissues. The differential transgene localization between preinjury and postinjury injection can be
used to optimize treatment strategies. Highly localized postinjury injection appears advantageous for treatments
targeting repair cells. The more generalized and controllable reservoir of transgene expression following AAV
injection before anterior cruciate ligament transection (ACLT) suggests an intriguing concept for prophylactic de-
livery of joint protective factors to individuals at high risk for early osteoarthritis (OA). Successful external control of
intra-articular transgene expression provides an added margin of safety for these potential clinical applications.
Introduction
Traumatic and degenerative injuries to articular car-tilage are a leading cause of disability. The limited healing
potential of articular cartilage contributes to development of
osteoarthritis (OA). OA, whether idiopathic or posttraumatic,
develops over many years and patients frequently need chronic
treatment. Common medications for OA include nonselec-
tive, nonsteroidal, anti-inflammatory drugs (NSAIDs) (Re-
commendations for the Medical Management, 2000; Evans et al.,
2004). Daily long-term use of these drugs, however, is not
without significant complications. NSAID therapy results in
systemic side effects and was responsible for 16,500 deaths per
year in the United States (Singh et al., 2006). As such, there are no
disease-modifying treatments for osteoarthritis or to reestablish
cartilage homeostasis (Izal et al., 2008). Posttraumatic osteoar-
thritis affects only the injured joint. Hence, delivery of bioactive
agents in a localized manner to the involved joint is an attractive
therapeutic option (Singh, 2012).
A novel treatment strategy for localized treatment is gene
therapy, utilizing viral vectors, such as adeno-associated vi-
rus (AAV), to deliver therapeutic proteins of interest to af-
fected joints to enhance joint repair or to prevent cartilage
degradation. Recombinant AAV is a promising delivery ve-
hicle for articular cartilage with the advantages of sustained
transgene expression, reduced potential for host immune
response, and the capacity to transduce both dividing and
nondividing cells in vivo and in vitro (Ulrich-Vinther et al.,
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2002; Lee et al., 2011). The viral vector is derived from an
endemic, nonpathogenic parvovirus, and intra-articular in-
jection of AAV has been used in clinical trials for delivery of
bioactive substances (Mease et al., 2010; High and Aubourg,
2011). Numerous serotypes of AAV exist, each serotype with
different preferential targets (Goater et al., 2000). AAV5 has
recently been suggested to have better transduction effi-
ciency in rodent arthritic joints. However, AAV2 has the best
defined safety profile and it is used in clinical trials (Mueller
and Flotte, 2008).
A recently published study from our laboratory has shown
both stable and persistent reporter transgene expression at
one year after a single intra-articular injection of AAV (Payne
et al., 2011). Most of the AAV transduction occurred in the
intra-articular soft tissues covered with synovial cells, with
limited articular chondrocyte transduction. This is consistent
with other studies, as vector penetration through the dense
cartilage extracellular matrix is restricted (Goater et al., 2000;
Evans et al., 2004). However, high-level expression of trans-
gene product was possible from the soft tissues.
To improve effectiveness of treatments in which timing of
administration are important and to provide an additional
margin of safety, controllable vectors have been developed to
limit treatment time/dosage to the minimal needed to
achieve therapeutic efficacy. One novel system is the tetra-
cycline (Tet)-on promoter, in which control is facilitated by
using tetracycline as an activator of the promoter, stimulat-
ing transgene expression only in the presence of the drug
(Gossen and Bujard, 1992). Previous studies in our laboratory
have successfully modulated gene expression utilizing the
Tet-on system and doxycycline, a tetracycline analog (Payne
et al., 2011). However, as intact/undamaged articular carti-
lage is unlikely to require treatment, AAV administration
strategies in the setting of joint injury will provide invaluable
information to improve gene therapy strategies for joint
restoration.
This study tests the hypotheses that (1) in vivo AAV trans-
gene expression localizes to the cartilage when AAV is ad-
ministered postinjury, (2) AAV injection preinjury leads to the
creation of a soft tissue reservoir that persistently expresses
transgene products at high levels, and (3) in vivo transgene
signal can be externally controlled after joint injury using oral
doxycycline. Two surgically created unilateral joint injuries of
high clinical relevance will be studied: osteochondral defect
(OCD) and anterior cruciate ligament transection (ACLT).
Materials and Methods
AAV preparation
Double-stranded AAV serotype 2 (AAV2) vectors were
produced, purified, and vector genome (vg) titer determined
as previously described (Rehman et al., 2005). AAV2s with
constitutively active cytomegalovirus (CMV) promoter in-
cluded AAV2-CMV-Luciferase (Luc) and AAV2-CMV
reverse-tetracycline-controlled transactivator (rtTA). AAV2
with tetracycline response element (TRE) promoter included
AAV2-TRE-Luc.
Animal studies
Animal experiments were performed following a Uni-
versity of Pittsburgh Institutional Animal Care and Use
Committee (IACUC)-approved protocols 0901937 and
1103868. Longitudinal in vivo study was performed using 48
3-month-old male Sprague Dawley rats (Harlan and Hilltop
Lab Animals).
In vitro explant AAV transduction
Femoral explants harvested from 3-month-old Sprague
Dawley rats (Harlan) were washed in phosphate buffered
saline (PBS) with 2% penicillin-streptomycin (pen/strep,
both from Gibco) and incubated for 2–3 days in 37C, 5%
CO2 in 1:1 ratio Dulbecco’s modified Eagle medium (DMEM)
and F-12 (DMEM/F-12, Gibco), 10% fetal bovine serum (FBS,
Gibco), 2% pen/strep, and 1% amphotericin B (Invitrogen).
The explants were divided into three groups in triplicate:
no-AAV control, intact with AAV, and injury with AAV. The
explants from the latter two groups were transduced with
AAV2-CMV-Luc at a concentration of 80,000 vector genomes
(vg)/cell in serum-free DMEM/F-12. After 1-hr incubation,
fresh DMEM/F-12, 10% FBS, 2% pen/strep, and 1% am-
photericin B were added to the culture. The culture media
was changed after 2 days. The explants were imaged after 96
hours post-AAV transduction, using IVIS Imaging System
200 (Xenogen), by adding 10 lL of 30 mg/mL D-Luciferin
Potassium Salt (Caliper Life Sciences) per 1 mL of culture
media. The images were taken at 1-min exposure.
Animal surgeries
Twenty-four rats underwent unilateral OCD surgeries,
while the other 24 rats underwent ACLT surgeries as pre-
viously described (Williams et al., 1982; Lee et al., 2013).
Briefly, all the procedures were carried out while the animals
were anesthetized with inhalation of isoflurane (Phoenix
Pharmaceuticals): 2–5% for induction and 0.25–4.0% for
maintenance. Rat knee joints were exposed via medial
parapatellar and medial patellar tendon approaches. The
patella was dislocated laterally and the knee was flexed. For
the OCD surgeries, the midpoint of the femoral trochlea was
identified and a 1.5-mm carbide-tipped drill (Emil Lange/
ELA) was used to create an OCD approximately 1.0-mm
deep. The subchondral bone was penetrated, and bleeding
bone was observed. For the ACLT surgeries, ACL and pos-
terior cruciate ligament (PCL) were visualized with the aid of
a 3 · surgical loupe (Carl Zeiss). Forceps were used to pro-
tect the PCL, and the ACL was severed using a 1.5-mm
Cutting Edge Beaver Needle Blade (Becton, Dickinson and
Company). ACLT was confirmed with an anterior drawer
test. Following injury creation for both OCD and ACLT, the
joint spaces were washed with sterile saline, and both cap-
sule and skin were sutured using monofilament 4-0 mono-
cryl (Ethicon). An intramuscular injection of 0.2–0.5 mg/kg
buprenorphine (Hospira) was administered twice per day for
2 days following surgery for analgesia.
AAV injections
AAV2-CMV-Luc was used to characterize the persistence
and localization of the transgene signal while AAV2-TRE-
Luc was used to characterize the external controllability of
the transgene signal using oral doxycycline.
Two different AAV injection time points were investigated
to compare the transgene expression levels: postinjury AAV
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injection and preinjury AAV injection. For the postinjury
AAV injection group, the viral vectors were injected bilat-
erally into both injured and intact joints at 1-week postinjury
for OCD rats and 3-weeks postinjury for ACLT rats. For the
preinjury AAV injection group, the AAVs were injected bi-
laterally into the joint. After 28 days, when the transgene
expression level has stabilized, the animals underwent uni-
lateral joint surgeries, either OCD or ACLT.
Each knee was given a total of 50 lL of AAVs, containing
2.5 · 1010 vg of either AAV2-CMV-Luc or AAV2-TRE-Luc
and an equal amount of AAV2-CMV-rtTA by single intra-
articular injection. During the injection procedures, animals
were anesthetized with gaseous isoflurane. Six rats were
used for each viral construct per injury model per AAV in-
jection time points.
External control of transgene expression
To induce expression of luciferase in the animals injected
with AAV2-TRE-Luc, the rats were administered drinking
water containing doxycycline (Sigma) at a concentration of
2 mg/mL for 7 days, followed by its removal. To ensure fresh
supply of doxycycline, the water was replaced every day and
protected from light using amber drinking bottles. Addition of
doxycycline to the drinking water was performed at 14 days, 3
months, and 6 months following AAV injection for postinjury
AAV-injected animals and following surgery for preinjury
AAV-injected animals. Rats injected with AAV2-CMV-Luc
had regular drinking water for the duration of the study.
Longitudinal in vivo live animal imaging
At each imaging time point, rats were anesthetized with
isoflurane inhalation, followed by a 50-lL intra-articular in-
jection of 30 mg/mL D-Luciferin Potassium Salt substrate
(Caliper). After 5 min, rats were placed in and imaged with an
IVIS 200 optical imaging system. Rats injected with AAV2-
CMV-Luc were imaged every week for the first month, and
monthly thereafter, until 6 months post-AAV injection, when
the rats were sacrificed. On the day of sacrifice following
regular imaging as detailed above, rats received a 400-lL in-
traperitoneal injection of 30 mg/mL D-Luciferin Potassium
Salt substrate (Goldbio) to determine if any signal was present
outside the joint. The joint was then opened to image the intra-
articular tissues. Rats injected with AAV2-TRE-Luc were im-
aged three times for every oral doxycycline stimulation cycle:
predoxycycline time point prior to addition of doxycycline, 7
days following doxycycline addition, and 7 days following
doxycycline removal. These rats were sacrificed at 6 months
post-AAV injection as well, following the third doxycycline
stimulation cycle. All the rats were sacrificed via CO2 as-
phyxiation and subsequent thoracotomy.
Viral genome copy determination
Following sacrifice, the knee joints of n = 3 rats/group
were further dissected to isolate chondrocytes from femoral
and tibial cartilages to detect viral DNA copy as previously
described (Qiao et al., 2012). Briefly, cartilage pieces from
each of the femoral and tibial cartilages were separately
stored dry in - 80C freezer until analysis. Total DNA was
extracted using DNeasy blood and tissue kit (Qiagen), and
vector copy number was determined with a 7300 real-time
PCR system (Applied Biosystems). The rat glucagon gene
was used as the endogenous control. The sequences for rat
glucagon primers and probes were as follows: Glucagon-
real-F (rat), AAG GGA CCT TTA CCA GTG ATG TG;
Glucagon-real-R (rat), ACT TAC TCT CGC CTT CCT CGG;
Taqman rat glucagon probe, FAM-cag caa agg aat tca-MGB.
Luciferase primers and probes were designed for AAV viral
genome detection: Luc-F, TTG ACC GCC TGA AGT CTC
TGA; Luc-R, ACA CCT GCG TCG AAG ATG TTG; Luc-
probe, FAM- ccg ctg aat tgg aat c-MGB. The genome copy
number is expressed as viral genome copies per diploid
nuclear genome ([vector copy number/endogenous con-
trol] · 2). The sensitivity of the assay was 0.001 vector copies
per cell.
Statistical analyses
All the statistical analyses were performed using Statistical
Packages for Social Studies (SPSS) 17.0 (IBM). Results were
judged for significance at p < 0.05, unless otherwise noted.
Explant data were observed in triplicate (Fig. 1, n = 3). In vivo
animal data were observed using independent animals, with
n = 6 per group. All the data were tested for assumptions
of parametric data: Shapiro-Wilk for normality of data dis-
tribution and Levine’s for homogeneity of variance. The
parametric bioluminescence data for the explant study is
represented as median and interquartile range boxplots and
analyzed using one-way independent analysis of variance
(ANOVA) with post hoc Tukey (Fig. 1) (OCD, Figures 2 and 3;
ACLT Figures 4 and 5). The longitudinal bioluminescence
data for the animal studies assessing the persistence and
magnitude of the AAV transgene are represented as line
graphs – standard error of mean (SEM) and were analyzed
using two-way mixed ANOVA, with main independent
variables of joint injury status as paired variable and time as
repeated variable (Figs. 2 and 4). Friedman’s ANOVA test
with a Bonferroni correction was used as a post hoc test to
assess the effect of time on each of the injured and intact
joints when the interaction effect between the joint injury
status and time was significant (Fig. 4B), with p < 0.025 (0.05/
2 comparisons) considered significant. Further post hoc
analysis of each consecutive time point was performed using
Wilcoxon test and a Bonferroni correction, with p < 0.006
(0.025/4 comparisons) considered significant for the intact
joint (Fig. 4B). The bioluminescence data assessing control-
lability of transgene expression were analyzed using one-
way repeated measured ANOVA (Fig. 6). Viral DNA copy
number was determined from tissues from n = 2–3 per group
and shown as mean – SEM in Table 1.
Results
In vitro explant AAV transduction
Transgene expression was observed from femoral carti-
lage explants transduced with AAV-CMV-Luc (Fig. 1). The
bioluminescence signal was greater in no-injury/AAV
( p = 0.046) and scratch/AAV ( p = 0.008) groups compared
to no-injury/no-AAV control group. While no difference
was observed between the two AAV-CMV-Luc–transduced
groups ( p = 0.313), the mechanical scratch injury model where
the condyles were scratched with a blade showed brighter
bioluminescence at both lateral and medial condyles.
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FIG. 1. Explant AAV transduction
of rat femoral cartilage. Rat femoral
cartilage explants were either
scratched or kept intact (No Injury),
after which they were transduced
with AAV2-CMV-Luc. Luciferase
signal was detected after 96 hr. (A)
Representative images of biolumi-
nescence signal from the explants.
(B) Median and interquartile range
of bioluminescence for the different
explant groups (n = 3; *p < 0.05 ver-
sus No Injury/No AAV Control
group). AAV, adeno-associated vi-
rus; CMV, cytomegalovirus; Luc,
luciferase.
FIG. 2. Persistence of AAV transgene in the OCD injury model. Persistence of in vivo transgene expression in OCD-injured
joints with a single intra-articular injection of AAV-CMV-Luc post-OCD (A and B) or pre-OCD (C and D) were assessed via
bioluminescence. (A) Representative images of transgene signal from the OCD and intact joints at 7 days, 1 month, and 6
months following AAV-CMV-Luc injection 1 week after OCD injury. (B) Mean and SEM of bioluminescence observed in the
OCD and intact joints of all rats in the group for 6 months following AAV-CMV-Luc injection 1 week after OCD injury. (C)
Representative images of transgene signal from the OCD and intact joints injected with AAV-CMV-Luc 4 weeks prior to OCD
injury at pre-OCD, 1-month, and 6-month time points. (D) Mean and SEM of bioluminescence observed in the OCD and
intact joints of all rats in the group for 6 months following OCD injury in joints injected with AAV-CMV-Luc 4 weeks prior
(n = 6/group). OCD, osteochondral defect.
460 LEE ET AL.
AAV transduction in OCD injury
AAV transgene expression was persistent in both the
OCD and intact joints whether the AAV was injected post-
or pre-OCD injury (Fig. 2). However, the magnitude of the
transgene expression levels in the OCD joints was different
between the two AAV injection time points. For the knees
with AAV injected post-OCD, there was a significant main
effect of the injury status on the bioluminescence level
( p = 0.015), where the OCD knees had lower signal than the
intact knees (Fig. 2B). On the other hand, for the knees with
AAV injected pre-OCD, the main effect of the injury status
on the bioluminescence level was nonsignificant ( p = 0.924,
Fig. 2D). In addition, the luciferase expression remained
unchanged from the pre-OCD time points. For both the
AAV injection time-point groups, there was a nonsignifi-
cant main effect of time on the bioluminescence level
( p = 0.175 for post-OCD AAV injection and p = 0.185 for pre-
FIG. 4. Persistence of AAV transgene in ACLT injury model. Persistence of in vivo transgene expressions in ACL-transected
joints with a single intra-articular injection of AAV-CMV-Luc post-ACLT (A and B) or pre-ACLT (C and D) were assessed via
bioluminescence. (A) Representative images of transgene signal from the ACLT and intact joints at 7 days, 1 month, and 6
months following AAV-CMV-Luc injection 3 weeks after ACL transection. (B) Mean and SEM of bioluminescence observed
in the ACLT and intact joints of all rats in the group over 6 months following AAV-CMV-Luc injection 3 weeks after ACL
transection. (C) Representative images of transgene signal from the ACLT and intact joints injected with AAV-CMV-Luc 4
weeks prior to ACL transection at pre-ACLT, 1-month, and 6-month time points. (D) Mean and SEM of bioluminescence
observed in the ACLT and intact joints of all rats in the group for 6 months following ACL transection in joints injected with
AAV-CMV-Luc 4 weeks prior (n = 6/group). ACLT, anterior cruciate ligament transection.
FIG. 3. Localization of AAV transgene in the OCD injury model. Intra-articular localization of transgene expressions in OCD-
injured joints with a single intra-articular injection of AAV-CMV-Luc were assessed after exposing the joint on the day of sacrifice
using the IVIS optical imaging system. (A) Representative intra-articular images of transgene signal from the exposed OCD and
intact joints that were injected with AAV-CMV-Luc 1 week after OCD injury. (B) Representative intra-articular images of
transgene signal from the exposed OCD and intact joints that were injected with AAV-CMV-Luc 4 weeks prior to OCD injury.
AAV TRANSGENE EXPRESSION IN INJURED JOINTS 461
OCD AAV injection): the transgene magnitude remained con-
stant throughout the duration of the study for each of the joints.
The interaction effect between the joint injury status and the
time was nonsignificant in both cases as well ( p = 0.182 for post-
OCD AAV injection and p = 0.921 for pre-OCD AAV injection).
Upon exposing the intra-articular space, the location of
transgene expression was different in the OCD injured knees
between the two different AAV injection time points (Fig. 3).
For both of the AAV injection time points, the intact joints
had the diffuse and high magnitude signal in the exposed
infrapatellar fat pad. However, for the OCD injured joints, the
bioluminescence signal was concentrated to the injured femur
in the post-OCD AAV-injected knees (Fig. 3A), whereas the
signal was more diffusely found in intra-articular soft tissues,
mainly the fat pad in the pre-OCD AAV-injected knees (Fig.
3B). Hence, the pre-OCD AAV-injected knees had transgene
signal location similar to those of the intact joints. The anal-
ysis of the cartilage tissues confirmed the presence of viral
DNA genome copies in the chondrocytes isolated from the
femoral and tibial cartilages of OCD-injured joints (Table 1).
AAV transduction in ACLT injury
Similar to the OCD injury model, the transgene expression
was persistent in both the ACLT and intact joints, and for
both post-ACLT and pre-ACLT AAV injections (Fig. 4). The
magnitude of the bioluminescence levels in the ACLT joints
was again different between the two AAV injection time
points. For the joints with AAV injected post-ACLT, there
was a significant main effect of the injury status ( p = 0.001).
The ACLT joints had lower signal than the intact joints (Fig.
4B). For the knees with AAV injected pre-ACLT, on the other
hand, the main effect of the injury status was nonsignificant,
with no change in transgene expression from the pre-ACLT
time points ( p = 0.279, Fig. 4D). The main effect of time on the
bioluminescence level was significant for the post-ACLT
AAV-injected group ( p = 0.010) and nonsignificant for the
pre-ACLT AAV-injected group ( p = 0.531). The interaction
effect between the joint injury status and the time was sig-
nificant for post-ACLT AAV injection study group ( p = 0.011)
and nonsignificant for pre-ACLT AAV injection study group
( p = 0.872). The effect of time in post-ACLT AAV injection
study group did not achieve significance for the ACLT joint
following post hoc analysis ( p = 0.992). For the intact joint, on
the other hand, the effect of time remained significant
( p = 0.003), necessitating additional post hoc testing. None-
theless, Wilcoxon test and a Bonferroni correction revealed
no significant differences between the consecutive time
points. Hence, the transgene magnitude remained constant
throughout the study period for all joints in post-ACLT and
pre-ACLT AAV injection groups.
Table 1. Viral DNA Copy Number in Different Cartilage Components of the Knee Joint
Injury AAV injection time point Cartilage components
Viral DNA copy number
(mean – SEM, copies/cell)
OCD Post-OCD Femoral cartilage 0.115 – 0.076
Tibial cartilage 0.151 – 0.125
Pre-OCD Femoral cartilage 0.061 – 0.033
Tibial cartilage 0.014 – 0.001
ACLT Post-ACLT Femoral cartilage 1.229 – 1.151
Tibial cartilage 0.602 – 0.599
Pre-ACLT Femoral cartilage 0.009 – 0.003
Tibial cartilage 0.004 – 0.001
Mean – SEM of viral DNA copy number detected in chondrocytes isolated from femoral and tibial cartilage of the AAV-transduced joint.
n = 2–3/group.
OCD, osteochondral defect; ACLT, anterior cruciate ligament transection.
FIG. 5. Localization of AAV transgene in ACLT injury model. Intra-articular localization of transgene expressions in ACL-
transected joints with a single intra-articular injection of AAV-CMV-Luc were assessed after exposing the joint on the day of sacrifice
using the IVIS optical imaging system. (A) Representative intra-articular images of transgene signal from the exposed ACLT and
intact joints that were injected with AAV-CMV-Luc 3 weeks after ACL transection. (B) Representative intra-articular images of
transgene signal from the exposed ACLT and intact joints that were injected with AAV-CMV-Luc 4 weeks prior to ACL transection.
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When the intra-articular space was exposed, the localiza-
tion of bioluminescence signal was different in the ACLT
joints between the two different AAV injection time points as
well (Fig. 5). Consistent with the intact sides of the OCD-
injury model animals, the intact joints showed diffuse signal
in the exposed infrapatellar fat pad for both of the AAV in-
jection time points. In addition, the diffuse bioluminescence
signal was found in the infrapatellar fat pad for the pre-ACLT
AAV-injected, ACL-transected joints, which overwhelmed
signal detection from the cartilage (Fig. 5B). However, for the
post-ACLT, AAV-injected, ACL-transected joints, the biolu-
minescence signal was lower in the intra-articular soft tissues,
but some region of concentrated signal was detected in the
cartilage (Fig. 5A). The analysis of the cartilage tissues con-
firmed the presence of viral DNA genome copies in the
chondrocytes isolated from the femoral and tibial cartilages of
ACLT-injured joints at both injection time points (Table 1).
External control of AAV transgene expression
in injured joints
The 7-day oral doxycycline cycle to induce transgene ex-
pression was performed starting at three different time points
throughout the study in animals that received the AAV2-TRE-
Luc. For all three doxycycline stimulation cycles, there was an
upregulation of gene expression with the addition of Dox
( p < 0.05) and a downregulation following its removal from the
drinking water ( p < 0.05) of both the OCD- and ACLT-injured
joints, and from both the post- and preinjury AAV injection
time points (Fig. 6). However, the magnitude of transgene
upregulation was different between the two AAV injection time
points: those from postinjury AAV-injected joints achieved
lower mean fold increase in bioluminescence signal compared
to those from preinjury AAV-injected joints ( p < 0.001).
Discussion
Treatment or prevention strategies of pathologic pro-
cesses within articular joints are severely limited. Hence, a
successful delivery strategy for adequate levels of thera-
peutic molecules in a localized manner is critically important.
Gene therapy strategies, therefore, have gained a lot of at-
tention for arthritis treatment (Goater et al., 2000; Evans et al.,
2004). Numerous vectors are available for in vivo gene
transfer, such as naked DNA, retrovirus, adenovirus, etc.
However, most are limited in terms of safety, efficacy, and
FIG. 6. Controllability of AAV transgene in joint injury models. Intra-articular transgene expression in injured joints with a
single intra-articular injection of AAV-TRE-Luc postinjury (A and C) or preinjury (B and D) were assessed after three cycles
of doxycycline addition and removal using the IVIS optical imaging system. (A) Representative intra-articular images of
transgene signal from the OCD joints that were injected with AAV-TRE-Luc 1 week after OCD injury. (B) Representative
intra-articular images of transgene signal from the OCD joints that were injected with AAV-TRE-Luc 4 weeks prior to OCD
injury. (C) Representative intra-articular images of transgene signal from the ACLT joints that were injected with AAV-TRE-
Luc 3 weeks after OCD injury. (D) Representative intra-articular images of transgene signal from the ACLT joints that were
injected with AAV-TRE-Luc 4 weeks prior to ACL transection (*p < 0.05 compared to Day 0, Pre-Dox; #p < 0.05 compared to
Day 7, Dox + ; n = 6/group). Tre, tetracycline response element.
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duration (Ulrich-Vinther, 2007). AAV, on the other hand, is a
very promising vector system that may provide the best
balance between safety and in vivo gene delivery efficiency
(Evans et al., 2004). Methods to localize and control in vivo
transgene expression are important to enhance the thera-
peutic efficiency and safety of intra-articular AAV gene
therapy. This has been achieved in intact joints (Payne et al.,
2011). However, to more closely mimic the osteoarthritic
environment, AAV transduction to injured cartilage and
joints has been investigated.
We initially characterized the efficacy of AAV transduc-
tion in explant cultures of femoral cartilage. With 80,000 vg/
cell AAV2-CMV-Luc, significant transduction was observed
for rat femoral explants. There was no significant difference
with transduction efficacy between the two AAV-transduced
groups. However, the mechanical injury model where the
condyles were scratched with a blade showed high intensity
of luciferin flux at both lateral and medial condyles. This is
potentially due to the scratch injury creating a more perme-
able path to articular chondrocytes for AAV transduction.
Thus, we expected to have more AAV transduction in dam-
aged areas of articular cartilage.
Two commonly used joint injury models of high clinical
relevance were chosen: OCD and ACLT. The timing of AAV
injection, pre- or post-injury, permitted us to characterize the
effect of joint injury on AAV transduction and localization of
transgene expression. For both injury models, AAV trans-
duces and is mainly expressed by intra-articular soft tissues
of the intact sides, as shown in the previous study (Payne
et al., 2011). However, if the AAV is injected after joint injury,
as would likely be the case in a clinical setting, the transgene
signal localizes to the vicinity of the injured cartilage. As in
the case for the explant study, the injured cartilage, with
more permeable extracellular matrix, would have allowed
AAV to reach and transduce the chondrocytes/injury-
activated repair cells. The transgene expression from the soft
tissues was limited for both OCD- and ACLT- injured joints.
This can also be due to other reasons, such as increased
volume of synovial fluid in injured joints diluting the intra-
articular viral concentrations, injury-activated macrophages
clearing up the virus prior to effective transduction, or the
viral gene promoter shutting off in response to the injury
(Qiao et al., 2011).
It is also possible that the injury may have resulted in
more diffuse distribution of AAV transduction throughout
the joint and hence affected our ability to measure the total
signal strength if the signal strength did not reach the
threshold of detection. In contrast, when the AAV is injected
before injury, the transgene signal magnitude as well as lo-
calization was no different from those of the intact joints and
persisted following the surgical procedure. Transgene ex-
pression was mainly found in the intra-articular soft tissues
with minimally detectable viral DNA copies in chondrocytes
from the injured cartilage. This preinjury AAV injection data
makes the theory that the promoter shuts off in response to
injury less likely.
For the postinjury AAV injection time points, we chose 1
week for the OCD model to allow time for the acute in-
flammatory stage from the OCD surgery to subside. In ad-
dition, we hoped to have the repair cells from the underlying
bone marrow recruited to the site of defect to allow their
viral transduction. On the other hand, we chose 3 weeks
postinjury time point to inject the AAV in order for the ACLT
model to allow some cartilage damage from altered me-
chanical/biochemical forces following the joint instability.
The surgical trauma of either OCD or ACLT procedure
may have influenced the accuracy of joint injection. How-
ever, we have extensive experience in accurate intra-articular
(IA) injection of AAV and other substrates in rat knee joints
(Chu et al., 2010; Payne et al., 2011). In addition, we imaged
the preinjury AAV-injected joints with IA luciferin injection
at a weekly interval following surgery and found no differ-
ence in signal patterns from preinjury time points. Hence, we
are confident that the joint injections with either AAV or
luciferin substrate have been accurate following joint injury.
In order to image and quantify the luciferase transgene
signal, we utilized the IA route of luciferin substrate ad-
ministration. While the IA route introduces an unnecessary
variable compared to subcutaneous or intraperitoneal (IP)
injections, we chose the IA route due to cost and time re-
strictions. Compared to the IA route, IP injection required
eight-fold more volume of luciferin substrate, as well as five-
fold longer luciferin distribution time for optimal imaging.
Nonetheless, we have imaged rats in groups injected with
AAV2-CMV-Luc with IP administration of luciferin at 35
days postinjury. The bioluminescence signal pattern was no
different from those imaged and quantified using the IA
luciferin administration route the week prior (28-day post-
injury or the 1-month timepoint). As previously mentioned,
IA injections into rat stifle joints have been extensively and
reliably utilized in our previous studies (Chu et al., 2010;
Payne et al., 2011).
The controllability of gene expression in intact and injured
joints is also important since gene expression may not be
needed for a prolonged period of time to have a beneficial
effect, and it provides an added means of safety. We have
shown this controllability in all the injury models, whether
the AAV was injected post- or pre-injury using oral admin-
istration of doxycycline in drinking water. The magnitude of
doxycycline-induced transgene upregulation, however, was
different between the two AAV injection time points. The
transgene signal was lower for the postinjury AAV-injected
animals compared to preinjury AAV-injected animals, which
is consistent with the transgene magnitude found in AAV-
CMV-Luc–injected animals. Doxycycline is an analog of
tetracycline, an antimicrobial agent that is safely used in
humans. It has a long-term record of relative safety and few
recognized adverse effects, namely sun sensitivity, monilial
vaginitis, and nonspecific gastrointestinal symptoms. In a
human trial that used doxycycline for 30 months, only these
three side effects were observed (Brandt et al., 2005). No se-
rious adverse events, such as death, hospitalization, and
development of a life-threatening or debilitating condition,
were attributable to doxycycline. In addition, the use of
doxycycline as the transgene inducer molecule may have
added beneficial effect for cartilage protection. Doxycycline
inhibits collagen-degrading enzymes such as matrix me-
talloproteinases (MMPs), and has shown beneficial effects in
both OCD and ACLT injury models by preventing MMP
upregulation (Yu et al., 1992; Lee et al., 2013).
The differential transgene location between the two AAV
injection time points can be used to optimize AAV-mediated
cartilage repair strategies. The highly localized gene expres-
sion following AAV injection postinjury is advantageous for
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gene therapy strategies that deliver anabolic growth factors
that can aid in cartilage repair, especially genes that need to
specifically target chondrocytes to be effective. Such strate-
gies may include RNA interference against various cartilage
catabolites, such as aggrecanases/ADAMTSs (Song et al.,
2007), or chondrogenic growth factors that have adverse ef-
fects on other intra-articular soft tissues, such as transform-
ing growth factor (TGF)-b1. TGF-b1 has been shown to
increase chondrocyte matrix synthesis when its gene vector
was injected in the joint; however, its overexpression from
the synovium resulted in adverse fibrosis (Mi et al., 2003).
Our data showing external controllability of intra-articular
transgene expression through oral doxycycline supports use
of a tet-on construct to additionally minimize undesired ef-
fects by regulating temporal exposure to anabolic agents.
Diffuse signal, seen when AAV is injected before creation
of injury, is also of potential value, as it provides a model to
study the delivery of protective factors to individuals that
may be at high risk for joint injury or cartilage degeneration.
Although the virus does not specifically transduce chon-
drocytes, a high level of transgene expression from sur-
rounding soft tissues still allows for preventative therapeutic
approaches by using the soft tissue as a drug depot to release
protective molecules. The high intra-articular concentrations
of secreted products, such as cytokine antagonists, can
compete with inflammatory mediators that are upregulated
in disease states, to protect the cartilage. Synoviocytes release
numerous proinflammatory molecules in arthritic conditions
(Pasztoi et al., 2009). Hence, a strong tropism of AAV for the
synovium can be utilized to suppress expression of any of
these injurious compounds.
A cytokine antagonist interleukin-1-receptor antagonist
protein (IRAP) is an extensively studied molecule for such
reasons (Arend et al., 1998). This compound is especially
attractive due to its lack of any known agonist activities.
Adenoviral delivery of IRAP has led to chondroprotective
effect in equine osteoarthritic model of osteochondral frag-
mentation (Frisbie et al., 2002; Morisset et al., 2007). Addi-
tional in vivo studies using prophylactic AAV-IRAP are
planned using small animal joint-injury models. Successful
external control of intra-articular transgene expression with
oral doxycycline provides an added margin of safety for
potential prophylactic clinical applications.
The studies investigating AAV transduction in injured
joints are limited with prior work focused more on rheu-
matoid arthritis (Pan et al., 1999; Goater et al., 2000; Zhou
et al., 2011). Two groups used a transgenic mouse model that
spontaneously develops arthritis due to tumor necrosis fac-
tor (TNF)-a overexpression (Goater et al., 2000; Zhou et al.,
2011). Goater et al. (2000) reported increased AAV trans-
duction efficiency with increased degree of the joint disease
following an intra-articular injection of AAV, with synovio-
cytes as the primary target. In addition, in vitro transduction
efficiencies of synoviocytes extracted from the transgenic
mice increased with the treatment of these cells with dam-
aging agents, such as irradiation and TNF-a. However, their
study was done using single-stranded AAV, where the
second-strand synthesis is the limiting step in AAV trans-
gene expression. Hence, the injurious agents promote
DNA synthesis and thus transgene expression as well. The
use of double-stranded or self-complementary AAV has been
shown to improve AAV transgene expression (Kay et al.,
2009). Zhou et al. (2011) showed persistent transgene ex-
pression for 120 days following AAV-Luc injection in the
transgenic mouse joints; however, they did not compare their
bioluminescence level to intact joints, preventing a compar-
ison to our study. Another study investigated intra-articular
AAV transduction in Sprague Dawley rats damaged via a
joint injection of lipopolysaccharide (LPS) (Pan et al., 1999).
This study showed positive correlations between disease
severity and AAV transduction and between disease severity
and transgene expression. Again, however, these injury
models mimic inflammatory/rheumatoid arthritis rather
than osteoarthritis.
In summary, this study evaluated localization, persistence,
and controllability of AAV-induced intra-articular transgene
expression in two clinically relevant joint injury models.
While AAV transgene expression was localized to the soft
tissues of the uninjured joint and injured joints when AAV
was injected preinjury, AAV was able to transduce articular
chondrocytes within the cartilage matrix when injected fol-
lowing injuries. The explant data showing AAV transduction
of articular chondrocytes in damaged cartilage further sug-
gests that cartilage matrix injury may have facilitated entry
of more AAV into the cartilage. Differential transgene ex-
pression can be used to optimize AAV-mediated cartilage
repair strategies: postinjury AAV injection approaches
would directly target articular chondrocytes in diseased and
injured cartilage, and preinjury AAV injection would allow
intra-articular delivery of secreted anti-inflammatory factors
for sustained release from soft tissues to protect the joint.
Overall, these data support further study of the in vivo
therapeutic potential of AAV for safe and localized delivery
of bioactive substances to injured joints. This can aid in
cartilage repair as well as restoration and maintenance of
joint homeostasis as strategies to delay or prevent the onset
of debilitating osteoarthritis.
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